JP2024516096A5 - - Google Patents

Info

Publication number
JP2024516096A5
JP2024516096A5 JP2023561853A JP2023561853A JP2024516096A5 JP 2024516096 A5 JP2024516096 A5 JP 2024516096A5 JP 2023561853 A JP2023561853 A JP 2023561853A JP 2023561853 A JP2023561853 A JP 2023561853A JP 2024516096 A5 JP2024516096 A5 JP 2024516096A5
Authority
JP
Japan
Prior art keywords
rnai agent
sequence
nucleotide
agent according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023813 external-priority patent/WO2022216920A1/en
Publication of JP2024516096A publication Critical patent/JP2024516096A/ja
Publication of JP2024516096A5 publication Critical patent/JP2024516096A5/ja
Pending legal-status Critical Current

Links

JP2023561853A 2021-04-08 2022-04-07 終末糖化産物受容体の発現を阻害するためのRNAi剤、その組成物、及び使用方法 Pending JP2024516096A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172301P 2021-04-08 2021-04-08
US63/172,301 2021-04-08
US202263322603P 2022-03-22 2022-03-22
US63/322,603 2022-03-22
PCT/US2022/023813 WO2022216920A1 (en) 2021-04-08 2022-04-07 Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use

Publications (2)

Publication Number Publication Date
JP2024516096A JP2024516096A (ja) 2024-04-12
JP2024516096A5 true JP2024516096A5 (cg-RX-API-DMAC7.html) 2025-04-15

Family

ID=83545747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561853A Pending JP2024516096A (ja) 2021-04-08 2022-04-07 終末糖化産物受容体の発現を阻害するためのRNAi剤、その組成物、及び使用方法

Country Status (15)

Country Link
US (2) US12486502B2 (cg-RX-API-DMAC7.html)
EP (1) EP4319765A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516096A (cg-RX-API-DMAC7.html)
KR (1) KR20230167082A (cg-RX-API-DMAC7.html)
AU (1) AU2022254705A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020626A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213968A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002985A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013243A2 (cg-RX-API-DMAC7.html)
IL (1) IL307421A (cg-RX-API-DMAC7.html)
MX (1) MX2023011909A (cg-RX-API-DMAC7.html)
PE (1) PE20240766A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023552779A1 (cg-RX-API-DMAC7.html)
TW (1) TW202304474A (cg-RX-API-DMAC7.html)
WO (1) WO2022216920A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026516053A (ja) * 2023-05-05 2026-05-19 レイジ バイオテック ピーティワイ エルティーディー オリゴヌクレオチドの投与
CN121586578A (zh) * 2023-08-24 2026-02-27 上海拓界生物医药科技有限公司 靶向RAGE的RNAi剂及其医药用途
EP4768586A1 (en) * 2023-09-27 2026-07-01 Changchun Genescience Pharmaceutical Co., Ltd. NEW ARNSI, COMPOSITION, INCLUDING IT AND USE
TW202516008A (zh) * 2023-09-27 2025-04-16 大陸商上海拓界生物醫藥科技有限公司 含三唑基化合物、製備方法及用途
CN120309684A (zh) 2024-01-15 2025-07-15 武汉人福创新药物研发中心有限公司 靶向化合物及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
CA2371824A1 (en) 1999-02-20 2000-08-24 Merck Patent Gesellschaft Mit Beschraenkter Haftung .beta.-alanine derivatives
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
DE19929410A1 (de) 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
MXPA05001758A (es) 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2005051995A2 (en) 2003-11-19 2005-06-09 Curagen Corporation Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same
EP2990410A1 (en) 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
US20080213249A1 (en) 2006-07-07 2008-09-04 The Scripps Research Insitute Use of Retro-Aldol Reaction to Generate Reactive Vinyl Ketone for Attachment to Antibody Molecules by Michael Addition Reaction for Use in Immunostaining and Immunotargeting
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
US20110003858A1 (en) 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
WO2009069727A1 (ja) 2007-11-28 2009-06-04 Fujifilm Corporation 生体高分子およびポリペプチドの化学修飾方法
CN102596922A (zh) 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
CN105017420B (zh) 2012-02-17 2019-05-28 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
EP2650013A1 (en) 2012-04-10 2013-10-16 Deutsches Krebsforschungszentrum Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
JP2014029990A (ja) 2012-06-29 2014-02-13 Sharp Corp 窒化物半導体装置の電極構造およびその製造方法並びに窒化物半導体電界効果トランジスタ
PT2978840T (pt) 2013-03-26 2021-01-06 Univ Of Artois Um modelo de barreira hematoencefálica humana derivado de células estaminais
JP2015040181A (ja) 2013-08-20 2015-03-02 学校法人立命館 カロテノイドの新規用途、並びにバリア機能改善薬のスクリーニング方法
BR112016004153A2 (pt) 2013-08-28 2019-09-17 Caris Life Sciences Switzerland Holdings Gmbh "método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero
EP2913064A1 (en) 2014-02-26 2015-09-02 celares GmbH Branched drug-linker conjugates for the coupling to biological targeting molecules
KR101602261B1 (ko) * 2014-04-01 2016-03-10 연세대학교 산학협력단 폴리플렉스 전달 시스템을 포함하는 부정맥 치료 또는 예방용 조성물
WO2015160770A1 (en) 2014-04-15 2015-10-22 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
WO2015179823A2 (en) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Lung localized inhibitors of alpha(v)beta 6
US9803201B2 (en) 2015-03-17 2017-10-31 Arrowhead Pharmaceuticals, Inc. Disulfide-containing alkyne linking agents
TWI761305B (zh) 2015-05-29 2022-04-21 美商愛羅海德製藥公司 抑制Hif2α基因表現之組合物及方法
TWI912633B (zh) 2016-06-06 2026-01-21 美商愛羅海德製藥公司 5'-環-磷酸修飾之核苷酸
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
AU2017354041B2 (en) 2016-11-01 2024-02-01 Arrowhead Pharmaceuticals, Inc. Alpha-V beta-6 integrin ligands and uses thereof
SG11202002967SA (en) 2017-11-01 2020-05-28 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
CN120247964A (zh) 2018-02-17 2025-07-04 箭头药业股份有限公司 三炔连接剂和使用方法
WO2021029896A1 (en) 2019-08-15 2021-02-18 Lifesplice Pharma Llc Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use
EP4496579A2 (en) * 2022-03-22 2025-01-29 Arrowhead Pharmaceuticals, Inc. Subcutaneous delivery of rnai agents for inhibiting expression of receptor for advanced glycation end-products (rage)

Similar Documents

Publication Publication Date Title
JP2025185070A5 (cg-RX-API-DMAC7.html)
JP2020526192A5 (cg-RX-API-DMAC7.html)
JP2024539193A5 (cg-RX-API-DMAC7.html)
JP6899509B2 (ja) 呼吸器疾患関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体およびこれを含む呼吸器疾患予防または治療用組成物
JP6799058B2 (ja) アレル選択的な遺伝子編集およびその使用
CN102099474B (zh) 用于治疗炎症和赘生性细胞增殖的寡核苷酸
TW201803989A (zh) 拮抗b型肝炎病毒之組成物和藥劑及彼等之用途
JP2017512502A (ja) 新規の二重らせんオリゴrnaおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物
JP2008510019A5 (cg-RX-API-DMAC7.html)
US20130281518A1 (en) Method of treating inflammatory lung disease with suppressors of cpg oligonucleotides
JP2023519246A5 (cg-RX-API-DMAC7.html)
CN1247473A (zh) 治疗与呼吸失调和肺部炎症相关的疾病和症状的药剂和方法
TW202221122A (zh) B型肝炎患者之寡核苷酸治療
WO1998023294A9 (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
JP2010500291A5 (cg-RX-API-DMAC7.html)
JP4903984B2 (ja) オリゴヌクレオチドのinvivoでの効率を増加するおよび哺乳動物において炎症を阻害するための方法
JP2024520522A5 (cg-RX-API-DMAC7.html)
TW202304474A (zh) 用於抑制晚期糖化終產物之受體表現之RNAi藥劑、其組合物及使用方法
TW202124413A (zh) 減少病毒分子含量之方法
JP2008516991A5 (cg-RX-API-DMAC7.html)
JP2015532100A (ja) アンフィレギュリンに特異的な二重鎖オリゴrna、そのような二重鎖オリゴrnaを含む二重鎖オリゴrnaの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物
JP2024023235A5 (cg-RX-API-DMAC7.html)
TWI884297B (zh) mRNA奈米膠囊及其用於製備抗病毒藥物的用途
JP2023501352A5 (cg-RX-API-DMAC7.html)
JP2025513757A5 (cg-RX-API-DMAC7.html)